Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Sprycel For Gleevec-Resistant Leukemia To Get Committee Review At June ASCO Meeting

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Oncologic Drugs Advisory Committee will meet in Atlanta to review Bristol’s multi-targeted kinase inhibitor dasatinib for two leukemia indications.

You may also be interested in...



Bristol’s Sprycel To Launch “Within Days”

FDA grants dasatinib accelerated approval for all phases of chronic myeloid leukemia in patients resistant to or intolerant of Novartis’ Gleevec.

Bristol’s Sprycel To Launch “Within Days”

FDA grants dasatinib accelerated approval for all phases of chronic myeloid leukemia in patients resistant to or intolerant of Novartis’ Gleevec.

Sprycel Dose Reduction To Be Considered By Oncology Cmte. During ASCO Road Show

FDA’s Oncologic Drugs Advisory Committee will review Bristol-Myers Squibb’s data package for the Gleevec-resistant leukemia therapy dasatinib on June 2.

Topics

UsernamePublicRestriction

Register

PS064102

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel